Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Impact of Antiphospholipid Antibodies on Thrombin Generation During Sars-CoV2 Infection (TACIT2 Study)

  • Read more about Impact of Antiphospholipid Antibodies on Thrombin Generation During Sars-CoV2 Infection (TACIT2 Study)

Rehabilitation of Critically Ill Patients With SARS-CoV-2 Variants in ICU With Limited Resources

  • Read more about Rehabilitation of Critically Ill Patients With SARS-CoV-2 Variants in ICU With Limited Resources

COVID-19 Coagulopathy Extension Study

  • Read more about COVID-19 Coagulopathy Extension Study

Clinical and Biological Characterization of Post COVID-19 Syndrome

  • Read more about Clinical and Biological Characterization of Post COVID-19 Syndrome

Fluvoxamine for Long COVID-19

  • Read more about Fluvoxamine for Long COVID-19

COVID-19 Antibody and Reinfection Study

  • Read more about COVID-19 Antibody and Reinfection Study

Long Haul COVID Rehabilitation & Recovery Research Program

  • Read more about Long Haul COVID Rehabilitation & Recovery Research Program

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

  • Read more about Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

  • Read more about The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

Long-Covid in Patients Post Rehabilitation Treatment and Reintegration Into Everyday Life

  • Read more about Long-Covid in Patients Post Rehabilitation Treatment and Reintegration Into Everyday Life

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 132
  • Page 133
  • Page 134
  • Page 135
  • Current page 136
  • Page 137
  • Page 138
  • Page 139
  • Page 140
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA